U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Description

Insulin aspart, a human insulin analogue, is a rapid-acting, parenteral blood glucose-lowering agent. Insulin aspart was marketed under the brand name NovoLog for the treatment of adult patients with diabetes mellitus, for the control of hyperglycemia. The primary activity of the drug is the regulation of glucose metabolism. Insulin aspart binds to the insulin receptors on muscle and fat cells and lower blood glucose by facilitating the cellular uptake of glucose and simultaneously inhibiting the output of glucose from the liver. This drug has an off-label treatment for gestational diabetes (temporary diabetes caused by diabetes).

Approval Year

2000
171
Targets

Targets

Primary TargetPharmacologyConditionPotency
Insulin receptor
13
Target ID: P06213
Gene ID: 3643.0
Gene Symbol: INSR
Target Organism: Homo sapiens (Human)
Agonist
2678
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8429
NOVOLOG

Approved Use

NovoLog™ is indicated for the treatment of adult patients with diabetes mellitus, for the control of hyperglycemia. Because NovoLog™ has a more rapid onset and a shorter duration of action than human regular insulin, NovoLog™ should normally be used in regimens together with an intermediate or long-acting insulin.

Launch Date

2000
PubMed

PubMed

TitleDatePubMed
Efficacy of biphasic insulin aspart in patients with type 2 diabetes.
2005

Sample Use Guides

In Vivo Use Guide
NovoLog™ (insulin aspart) should be administered by subcutaneous injection in the abdominal wall, the thigh, or the upper arm. Injection sites should be rotated within the same region. As with all insulins, the duration NovoLog™ should generally be given immediately before a meal. The dosage of NovoLog™ should be individualized and determined, based on the physician's advice, in accordance with the needs of the patient. The total daily individual insulin requirement is usually between 0.5 - 1.0 units/kg/day.
Route of Administration: Other
Name Type Language
INSULIN ASPART
EMA EPAR   EP   INN   MI   USAN   USP-RS   WHO-DD  
INN   USAN  
Official Name English
INA-X14
Code English
Insulin aspart protamine [WHO-DD]
Common Name English
INSULIN ASPART [USAN]
Common Name English
INSULIN ASPART [JAN]
Common Name English
INSULIN ASPART [MI]
Common Name English
INSULIN,ASPART PROTAMINE
VANDF  
Common Name English
insulin aspart [INN]
Common Name English
INSULIN,ASPART,HUMAN/RDNA
Common Name English
FIASP FLEXTOUCH
Brand Name English
INSULIN ASPART [USP MONOGRAPH]
Common Name English
FIASP
Brand Name English
28(SUP B)-L-ASPARTIC ACID-INSULIN (HUMAN)
Common Name English
ASPART
Common Name English
ASPART INSULIN
Common Name English
INSULIN ASPART RECOMBINANT [ORANGE BOOK]
Common Name English
RYZODEG 70/30 COMPONENT INSULIN ASPART
Brand Name English
Insulin aspart [WHO-DD]
Common Name English
INSULIN, ASPART, HUMAN
Common Name English
INSULIN, ASPART PROTAMINE, HUMAN
Common Name English
INSULIN ASPART [USP-RS]
Common Name English
INSULIN ASPART [EMA EPAR]
Common Name English
NN-1218
Code English
B-28-ASP-INSULIN
Code English
INSULIN-X14
Code English
INSULIN ASPART PROTAMINE RECOMBINANT [ORANGE BOOK]
Common Name English
NOVORAPID
Brand Name English
NN1218
Code English
ASPART-PH20
Common Name English
INSULIN ASPART COMPONENT OF RYZODEG 70/30
Brand Name English
B28-ASP-INSULIN
Code English
NOVOLOG
Brand Name English
Insulin aspart protamine (crystalline) [WHO-DD]
Common Name English
INSULIN B28(ASP) PROTAMINE RECOMBINANT HUMAN
Common Name English
INSULIN,ASPART PROTAMINE [VANDF]
Common Name English
INSULIN X14
Code English
INSULIN ASPART [EP MONOGRAPH]
Common Name English
Classification Tree Code System Code
NDF-RT N0000004931
Created by admin on Sat Dec 16 11:23:02 GMT 2023 , Edited by admin on Sat Dec 16 11:23:02 GMT 2023
WHO-ATC A10AD06
Created by admin on Sat Dec 16 11:23:02 GMT 2023 , Edited by admin on Sat Dec 16 11:23:02 GMT 2023
WHO-VATC QA10AD06
Created by admin on Sat Dec 16 11:23:02 GMT 2023 , Edited by admin on Sat Dec 16 11:23:02 GMT 2023
WHO-VATC QA10AD05
Created by admin on Sat Dec 16 11:23:02 GMT 2023 , Edited by admin on Sat Dec 16 11:23:02 GMT 2023
NDF-RT N0000004931
Created by admin on Sat Dec 16 11:23:02 GMT 2023 , Edited by admin on Sat Dec 16 11:23:02 GMT 2023
WHO-VATC QA10AB05
Created by admin on Sat Dec 16 11:23:02 GMT 2023 , Edited by admin on Sat Dec 16 11:23:02 GMT 2023
WHO-ATC A10AD05
Created by admin on Sat Dec 16 11:23:02 GMT 2023 , Edited by admin on Sat Dec 16 11:23:02 GMT 2023
NDF-RT N0000004931
Created by admin on Sat Dec 16 11:23:02 GMT 2023 , Edited by admin on Sat Dec 16 11:23:02 GMT 2023
WHO-ATC A10AB05
Created by admin on Sat Dec 16 11:23:02 GMT 2023 , Edited by admin on Sat Dec 16 11:23:02 GMT 2023
NDF-RT N0000175453
Created by admin on Sat Dec 16 11:23:02 GMT 2023 , Edited by admin on Sat Dec 16 11:23:02 GMT 2023
NCI_THESAURUS C581
Created by admin on Sat Dec 16 11:23:02 GMT 2023 , Edited by admin on Sat Dec 16 11:23:02 GMT 2023
Code System Code Type Description
DAILYMED
D933668QVX
Created by admin on Sat Dec 16 11:23:02 GMT 2023 , Edited by admin on Sat Dec 16 11:23:02 GMT 2023
PRIMARY
INN
7541
Created by admin on Sat Dec 16 11:23:02 GMT 2023 , Edited by admin on Sat Dec 16 11:23:02 GMT 2023
PRIMARY
CAS
116094-23-6
Created by admin on Sat Dec 16 11:23:02 GMT 2023 , Edited by admin on Sat Dec 16 11:23:02 GMT 2023
PRIMARY
ChEMBL
CHEMBL1201664
Created by admin on Sat Dec 16 11:23:02 GMT 2023 , Edited by admin on Sat Dec 16 11:23:02 GMT 2023
PRIMARY
SMS_ID
100000085441
Created by admin on Sat Dec 16 11:23:02 GMT 2023 , Edited by admin on Sat Dec 16 11:23:02 GMT 2023
PRIMARY
NCI_THESAURUS
C47563
Created by admin on Sat Dec 16 11:23:02 GMT 2023 , Edited by admin on Sat Dec 16 11:23:02 GMT 2023
PRIMARY
PUBCHEM
118984445
Created by admin on Sat Dec 16 11:23:02 GMT 2023 , Edited by admin on Sat Dec 16 11:23:02 GMT 2023
PRIMARY
RS_ITEM_NUM
1342037
Created by admin on Sat Dec 16 11:23:02 GMT 2023 , Edited by admin on Sat Dec 16 11:23:02 GMT 2023
PRIMARY
RXCUI
51428
Created by admin on Sat Dec 16 11:23:02 GMT 2023 , Edited by admin on Sat Dec 16 11:23:02 GMT 2023
PRIMARY
FDA UNII
D933668QVX
Created by admin on Sat Dec 16 11:23:02 GMT 2023 , Edited by admin on Sat Dec 16 11:23:02 GMT 2023
PRIMARY
MESH
D061267
Created by admin on Sat Dec 16 11:23:02 GMT 2023 , Edited by admin on Sat Dec 16 11:23:02 GMT 2023
PRIMARY
ChEMBL
CHEMBL1201496
Created by admin on Sat Dec 16 11:23:02 GMT 2023 , Edited by admin on Sat Dec 16 11:23:02 GMT 2023
PRIMARY
EPA CompTox
DTXSID10151274
Created by admin on Sat Dec 16 11:23:02 GMT 2023 , Edited by admin on Sat Dec 16 11:23:02 GMT 2023
PRIMARY
EVMPD
SUB08195MIG
Created by admin on Sat Dec 16 11:23:02 GMT 2023 , Edited by admin on Sat Dec 16 11:23:02 GMT 2023
PRIMARY
MERCK INDEX
m6295
Created by admin on Sat Dec 16 11:23:02 GMT 2023 , Edited by admin on Sat Dec 16 11:23:02 GMT 2023
PRIMARY Merck Index
USAN
KK-27
Created by admin on Sat Dec 16 11:23:02 GMT 2023 , Edited by admin on Sat Dec 16 11:23:02 GMT 2023
PRIMARY
RXCUI
352385
Created by admin on Sat Dec 16 11:23:02 GMT 2023 , Edited by admin on Sat Dec 16 11:23:02 GMT 2023
ALTERNATIVE
DRUG CENTRAL
4981
Created by admin on Sat Dec 16 11:23:02 GMT 2023 , Edited by admin on Sat Dec 16 11:23:02 GMT 2023
PRIMARY
EVMPD
SUB128590
Created by admin on Sat Dec 16 11:23:02 GMT 2023 , Edited by admin on Sat Dec 16 11:23:02 GMT 2023
ALTERNATIVE
WIKIPEDIA
Insulin aspart
Created by admin on Sat Dec 16 11:23:02 GMT 2023 , Edited by admin on Sat Dec 16 11:23:02 GMT 2023
PRIMARY
DRUG BANK
DB01306
Created by admin on Sat Dec 16 11:23:02 GMT 2023 , Edited by admin on Sat Dec 16 11:23:02 GMT 2023
PRIMARY
EVMPD
SUB25183
Created by admin on Sat Dec 16 11:23:02 GMT 2023 , Edited by admin on Sat Dec 16 11:23:02 GMT 2023
PRIMARY
ACTIVE MOIETY
INSULIN ASPART
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966